Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 276 - 300 of 10963 in total
Setmelanotide is the first available treatment for patients with pro-opiomelanocortin, proprotein subilisin/kexin type 1, or leptin deficiencies. It is an agonist of the melanocortin 4 receptor. Earlier attempts at agonizing MC4R (such as LY2112688) lead to successful weight loss, but also an increase in blood pressure and heart rate. Other...
Approved
Investigational
Matched Description: … [L24429] On May 4, 2023, it was approved by Health Canada.[L46327] ... is the first available treatment for patients with pro-opiomelanocortin, proprotein subilisin/kexin type ... [L24474] It is an agonist of the melanocortin 4 receptor. …
Matched Categories: … Receptor, Melanocortin, Type 4, agonists …
Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist used in the treatment of type II diabetes mellitus (T2DM). It is sold by Sanofi-Aventis under the brand name Adlyxin in the US and Lyxumia in the EU. Adlyxin recieved FDA approval July 28, 2016.
Approved
Matched Description: … Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist used in the treatment of type II diabetes …
Elranatamab is a bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager. It is a humanized immunoglobulin 2-alanine kappa antibody derived from two monoclonal antibodies (mAbs), an anti-BCMA mAb and an anti-CD3 mAb, each of which contributes one heavy chain and one light chain to drug structure. The resulting 4-chain bispecific...
Approved
Investigational
Matched Description: … [L47820] Elranatamab was also approved by the European Commission on December 8, 2023.[L50437] ... a humanized immunoglobulin 2-alanine kappa antibody derived from two monoclonal antibodies (mAbs), an ... anti-BCMA mAb and an anti-CD3 mAb,[A261060] each of which contributes one heavy chain and one light …
Technetium Tc-99m nofetumomab merpentan (Tc-99m nm) consists of a Fab fragment of an IgG2b of the pancarcinoma murine antibody NR-LU-10. The NR-LU-10 antibody is directed against a 40 kDa glycoprotein antigen expressed in a variety of cancers and some normal tissues.[FDA label] Tc-99m nm was developed by Boehringer Ingelheim Pharma...
Approved
Withdrawn
Matched Description: … II (Drug substance) with an active status. ... [FDA label] Tc-99m nm was developed by Boehringer Ingelheim Pharma KG and FDA approved on September 14 ... discontinued on August 13, 2013, but in the 2018 FDA submission list, it can be found as a substance type
Approved
Experimental
Mesuximide (or methsuximide) is an anticonvulsant medication. It is sold by Pfizer under the name Petinutin.
Approved
Matched Description: … Mesuximide (or methsuximide) is an anticonvulsant medication. …
Loxoprofen is a propionic acid derivative non-steroidal anti-inflammatory drug. It is marketed under the trade name Loxonin in Brazil, Mexico and Japan by Sankyo, as Loxomac in India, and as Oxeno in Argentina. A transdermal preparation was approved for use in Japan in January 2006.
Approved
Matched Iupac: … 2-{4-[(2-oxocyclopentyl)methyl]phenyl}propanoic acid
Matched Description: … Loxoprofen is a propionic acid derivative non-steroidal anti-inflammatory drug. ... A transdermal preparation was approved for use in Japan in January 2006. …
The human von Willebrand factor (vWF) is a human plasma-derived vWF, an endogenous large multimeric plasma glycoprotein involved in hemostasis. It serves a dual role in hemostasis by mediating platelet adhesion and aggregation at the site of blood vessel injury and stabilizing procoagulant factor VIII (FVIII). Exogenous sources of vWF...
Approved
Investigational
Matched Description: … It was first approved by the FDA in 2015. ... The human von Willebrand factor (vWF) is a human plasma-derived vWF, an endogenous large multimeric plasma …
Iodide has been investigated for the treatment of Goiter, Nodular.
Approved
Experimental
Givosiran is a small interfering RNA (siRNA) directed towards 5-aminolevulinic acid synthase, a critical enzyme in the heme biosynthesis pathway. It is manufactured by Alnylam Pharmaceuticals and was first approved for use in the United States in November 2019 for the treatment of adults with acute hepatic porphyria, a genetic...
Approved
Investigational
Matched Description: … Givosiran is a small interfering RNA (siRNA) directed towards 5-aminolevulinic acid synthase, a critical ... [L10202] Givosiran represents an important step forward in the treatment of acute hepatic porphyria as ... patisiran]), a new class of drugs promising an important and exciting step forward in the treatment of …
Rilonacept is a dimeric fusion protein consisting of portions of IL-1R and the IL-1R accessory protein linked to the Fc portion of immunoglobulin G1. Rilonacept functions as an interleukin 1 inhibitor and is used in the treatment of CAPS, also known as cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome...
Approved
Investigational
Matched Description: … Rilonacept functions as an interleukin 1 inhibitor and is used in the treatment of CAPS, also known as …
Matched Categories: … Receptors, Interleukin-1 Type I …
Plasminogen is a pro-enzyme (i.e. a zymogen) which is cleaved to form plasmin - also known as fibrinolysin - as part of the fibrinolytic pathway that breaks down fibrin blood clots. This pathway is activated when a clot is no longer needed or to prevent a clot from extending beyond...
Approved
Matched Description: … )[L34620] for the treatment of type 1 plasminogen deficiency (hypoplasminogenemia). ... to form on the mucous membranes of patients, providing an unmet medical need for patients with this ... [L34635] In June 2021, the FDA approved a plasma-derived plasminogen (Ryplazim, human plasminogen-tvmh …
Iodine is commonly used as an antiseptic for minor cuts and abrasions, preventing infections that may result from contaminated wounds. Additionally, iodine has been studied in the treatment of fibrocystic disease and breast cancer.[A3413,A192153,A192156,A192159]
Approved
Investigational
Matched Description: … Iodine is commonly used as an antiseptic for minor cuts and abrasions, preventing infections that may …
Matched Mixtures name: … New Chapter's D'adamo 4 Your Type Multiple for Type O …
Niraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. Niraparib is selective towards PARP-1 and PARP-2. First approved by the FDA on March 27, 2017, niraparib is used to treat epithelial ovarian, fallopian tube, or...
Approved
Investigational
Matched Description: … Niraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. ... [A253248] First approved by the FDA on March 27, 2017,[A253912] niraparib is used to treat epithelial ... [L43277] Niraparib was approved by the European Commission on November 16, 2017 [L43742] and by Health …
Copanlisib is a selective pan-Class I phosphoinositide 3-kinase (PI3K) inhibitor with preferential activity against the alpha and delta isoforms. PI3K, a lipid kinase that activates downstream signalling pathways involved in cell survival and growth, that exists in different isoforms and is often overexpressed in hematological malignancies. Copanlisib was granted accelerated...
Approved
Investigational
Polyethylene glycol (PEG) is a synthetic polymer produced via polymerization of ethylene oxide molecules to make joining units of ethylene glycol by an ether linkage.[A190975,A190978] PEGs are water-soluble polymers that can form hydrogen bonds in a ratio of 100 water molecules per one PEG molecule. Molecular weights of PEGs vary...
Approved
Vet approved
Matched Description: … produced via polymerization of ethylene oxide molecules to make joining units of ethylene glycol by an
Matched Mixtures name: … Peg-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate and Ascorbic Acid
A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985)....
Approved
Investigational
Imiquimod is an immune response modifier that acts as a toll-like receptor 7 agonist. Imiquimod is commonly used topically to treat warts on the skin of the genital and anal areas. Imiquimod does not cure warts, and new warts may appear during treatment. Imiquimod does not fight the viruses that...
Approved
Investigational
Matched Description: … Imiquimod is an immune response modifier that acts as a toll-like receptor 7 agonist. …
Matched Mixtures name: … Imiquimod 5% / Salicylic Acid 30% / Tretinoin 0.1% …
Mirvetuximab soravtansine-gynx (IMGN853) is an antibody-drug conjugate (ADC) formed by a monoclonal antibody (M9346A) that targets folate receptor alpha (FRĪ±), covalently joined by a cleavable disulfide linker to the genotoxic compound DM4 (also known as soravtansine or ravtansine).[A254392,L43967] DM4 is conjugated to the antibody with a drug-to-antibody ratio of 3.5:1....
Approved
Investigational
Matched Description: … Mirvetuximab soravtansine-gynx (IMGN853) is an antibody-drug conjugate (ADC) formed by a monoclonal antibody ... [A254382] After an ADC/receptor complex is formed, mirvetuximab soravtansine-gynx is internalized, and …
Lorpiprazole is a serotonin antagonist and reuptake inhibitor used for the treatment of major depressive disorder. It is a piperazinyl-triazole derivative.
Approved
Bromothalonil, also known as Methyldibromo glutaronitrile (MDBGN), is a widely used preservative that can be found in many personal hygiene and industrial products. It is also a known allergen and dermatological irritant that has been banned in many EU countries due to increasing rates of contact allergy . In 2005,...
Approved
Experimental
Pomalidomide, an analogue of thalidomide, is an immunomodulatory antineoplastic agent. FDA approved on February 8, 2013.
Approved
Matched Description: … FDA approved on February 8, 2013. ... Pomalidomide, an analogue of thalidomide, is an immunomodulatory antineoplastic agent. …
A carbamate derivative used as an alcohol deterrent. It is a relatively nontoxic substance when administered alone, but markedly alters the intermediary metabolism of alcohol. When alcohol is ingested after administration of disulfiram, blood acetaldehyde concentrations are increased, followed by flushing, systemic vasodilation, respiratory difficulties, nausea, hypotension, and other symptoms...
Approved
Matched Description: … A carbamate derivative used as an alcohol deterrent. …
Insulin aspart is a rapid-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the...
Approved
Matched Description: … Insulin is an important treatment in the management of Type 1 Diabetes (T1D) which is caused by an autoimmune ... with aspartic acid. ... 1 and Type 2 Diabetes. …
Hepatitis B Vaccine is an ingredient in the EMA-withdrawn product Quintanrix. It is marketed in Canada as Engerix B. It is also a part of Twinrix (Hep A/Hep B vaccine) available also in Canada. The hepatitis B virus induces a severe form of viral hepatitis. Other causative agents are hepatitis...
Approved
Withdrawn
Matched Description: … Hepatitis B Vaccine is an ingredient in the EMA-withdrawn product Quintanrix. ... The incubation period may be as long as 6 months, followed by a very complex clinical course of an acute ... resulted from a significant decline in the prevalence of hepatitis B antigen, the persistence of which is an
Displaying drugs 276 - 300 of 10963 in total